DiagnoCure's ImmunoCyt approved

The FDA granted marketing clearance for ImmunoCyt, a non-invasive bladder cancer diagnostic developed by DiagnoCure (TSE:CUR). Dako (Carpinteria, Calif.) will distribute the product in the U.S. CUR wa...